| Federation Bio Bags $50M to Engineer New Approach to Microbiome Drugs | Frank Vinluan | 10/06/20 | Boston |
| Sanofi Reaches $3.68B Deal to Buy Principia and Partnered MS Drug | Frank Vinluan | 08/17/20 | Europe |
| Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases | Frank Vinluan | 07/06/20 | Boston |
| Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More | Frank Vinluan | 06/05/20 | National |
| BCMA Delay: FDA Refuses Review of Bristol Drug, Asks for More Info | Frank Vinluan | 05/13/20 | New York |
| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch | Frank Vinluan | 03/26/20 | New York |
| Quench Bio Springs From Atlas With $50M for a New Take on Inflammation | Frank Vinluan | 01/27/20 | Boston |
| Biotech Roundup: Novartis on Hold, AMAG Vote, Neuro News & More | Frank Vinluan | 11/01/19 | National |
| Acorda Cuts Staff 25% and Restructures to Keep Focus on Parkinson’s Drug | Frank Vinluan | 10/24/19 | New York |
| Biogen’s Ehlers Leaving for Apple Tree, Steps Into Limelight as CEO | Frank Vinluan | 10/01/19 | New York |
| Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More | Ben Fidler | 09/13/19 | National |
| Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds | Frank Vinluan | 09/06/19 | Boston |
| Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More | Alex Lash | 08/30/19 | National |
| For GW Pharma CEO Justin Gover, The CBD Trend Started 20 Years Ago | Sarah de Crescenzo | 08/26/19 | San Diego |
| Skyhawk Inks Deal With Genentech for Cancer and Neuro Drug Discovery | Frank Vinluan | 07/16/19 | Boston |
| Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More | Frank Vinluan | 04/26/19 | National |
| Amid Acquisition Drama, Celgene Resubmits MS Drug for FDA Approval | Sarah de Crescenzo | 03/25/19 | New York |
| Adieu to Adu: Biogen’s Big Alzheimer’s Bet Flops, Shares Routed | Ben Fidler | 03/21/19 | Boston |
| Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More | Frank Vinluan | 03/15/19 | National |
| Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track | Frank Vinluan | 03/11/19 | New York |
| Alexion Hits Study Goals, Could Expand Blockbuster Drug to CNS | Frank Vinluan | 09/24/18 | Boston |
| Entasis Therapeutics and Principia Biopharma Join the IPO Queue | Frank Vinluan | 08/20/18 | Boston |
| Sangamo Bags TxCell, and a Next-Gen Cell Therapy Tech, for $84M | Ben Fidler | 07/23/18 | San Francisco |
| Pliant Picks Up $62M to Test Lung, Liver Fibrosis Drug in the Clinic | Frank Vinluan | 07/16/18 | San Francisco |
| Westphal’s Flex Pharma To Cut Jobs and Seek Sale After Clinical Flop | Ben Fidler | 06/13/18 | Boston |
| Akili Grabs $55M, Seeking FDA Approval of First Video Game Therapy | Jeff Bauter Engel | 05/09/18 | Boston |
| Roche Buys Inception 5 MS Program, Versant Funds New Venture | Bruce V. Bigelow | 04/04/18 | San Diego |
| Despite Pharma Ties, Some Patient Groups Protest High Drug Prices | Corie Lok | 03/12/18 | National |
| FDA Refuses to Review Celgene’s MS Drug, Says File “Insufficient” | Frank Vinluan | 02/27/18 | New York |
